Repacked prescriptions need origin-marking continuity
CBP's fact sheet explains that certain foreign-origin capsules, pills, tablets, lozenges, and troches are excepted from individual marking under the J-List, while the outermost container that ordinarily reaches the ultimate purchaser must show origin. When an in-scope medication is repacked for retail sale, the control question is whether that already-determined origin survives the exact container handoff with the required importer certification and downstream notice.